Baszucki Group Announces Six Recipients of the Metabolic Psychiatry Scholar Award for Emerging Scientific Leaders Advancing Mental Health Innovation
21.10.2025 09:00:00 EEST | Business Wire | Press release
Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award, a new initiative that supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The award represents a significant step forward in growing the rapidly advancing field of metabolic psychiatry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020666940/en/
Baszucki Group 2025 Metabolic Psychiatry Scholar Award Recipients
The six scholars will each receive up to $150,000 over 18 months for original research in metabolic psychiatry. The award program advances Baszucki Group’s mission to transform mental health outcomes through research at the intersection of metabolism, psychiatry, and neuroscience. Scholars will also receive mentorship, professional development, and communication support to amplify the impact of their research. The awards expand Baszucki Group’s research priorities into new diagnoses, genetics, novel combinations of treatment modalities, and implementation science.
“This award provides vital support for exceptional early-career scientists, allowing them to jumpstart innovative projects that don’t fit more traditional funding sources,” said Jan Ellison Baszucki, co-founder and president of Baszucki Group. “These outstanding awardees now have an opportunity to bring metabolic psychiatry approaches into the mainstream, paving the way for access to new treatments for the patients who need them most.”
The scholars’ work falls broadly into two subcategories: research and clinical capacity-building. Four of the awardees are engaged in translational and clinical research into the links between metabolic health and mental health:
Jacek Kolacz, PhD, Research Assistant Professor at The Ohio State University is an expert in brain-body responses to chronic stress and trauma recovery. His project, titled, “Enhancing PTSD Recovery with Metabolic-Augmented Psychotherapy” will investigate the combined effectiveness of cognitive processing therapy and metabolic therapy.
Eline Dekeyster, PhD, Assistant Professor at Leiden University, leads the Lifestyle Brain Interaction research group. Her project, “KETASE: Ketogenic Therapy for ASD: Sustainability and Efficacy,” will examine the clinical efficacy and long-term sustainability of ketogenic therapy for adults with autism, while also exploring biomarkers for outcome prediction.
Sean Nestor, MD, PhD, Assistant Professor at the University of Toronto, is a pioneer in combining neuroimaging and neuromodulation to understand the mechanisms of neurological and psychiatric disorders. His proposed work, “Ketogenic enhancement of therapeutic brain stimulation in treatment-resistant depression: A Randomized Controlled Pilot Trial,” will combine ketogenic therapy and transcranial magnetic stimulation in a first-of-its-kind trial.
Gabriel Fries, MSc, PhD, Assistant Professor at the University of Texas Health Science Center at Houston is an expert in the genetic and epigenetic underpinnings of severe mental illnesses. His project, “Deciphering the complex link between diet, metabolic dysfunction, and suicide risk,” will aim to identify the link between dietary and metabolic parameters and suicide risk.
Two of the awards will support clinical capacity-building projects, expanding support for ketogenic therapy across the UK and Canada:
Fabiano Alves Gomes, MD, MSc, PhD, Assistant Professor at McMaster University, is an expert in bipolar disorder and treatment-resistant depression and works extensively on implementing evidence-based interventions, including metabolic health and lifestyle factors. His project, “Integrating Nutritional Ketosis, Lifestyle Therapies, and Translational Research into Clinical Practice,” will establish a comprehensive Metabolic Psychiatry Program in Canada.
Erin L Bellamy, MSc, PhD, Chartered Psychologist, Ketogenic Specialist and Research Fellow at the University of East London provides Ketogenic Metabolic Therapy support to clients with a wide range of physical and mental health issues through private practice. Her project, titled, “Implementing Ketogenic Metabolic Therapy for Mental Illness: A Mixed-Methods Pilot Trial of an Online Psychoeducational and Support Program,” will expand on her pre-existing treatment program and support a rigorous evaluation protocol.
“The strength of the candidates who applied to this open call highlights the global enthusiasm to explore metabolic psychiatry's potential,” said Julie Milder, PhD, Director of Neuroscience at Baszucki Group. “From foundational research to clinical capacity building, their work has the potential to revolutionize patient treatment. We anticipate that this award marks the start of a lasting initiative that will continue to support the field for years to come.”
About Baszucki Group
Launched in 2021 by Roblox founder and Chief Executive Officer David Baszucki and best-selling author Jan Ellison Baszucki, Baszucki Group leverages private giving, impact investing, advocacy, storytelling and community building to drive foundational change. A primary objective of Baszucki Group is to transform mental health outcomes by supporting initiatives at the intersection of metabolism, psychiatry, and neuroscience. To learn more about metabolic approaches to mental disorders, including ketogenic therapy, visit Metabolic Mind, a nonprofit initiative of Baszucki Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251020666940/en/
Contacts
Baszucki Group media contact: media@baszuckigroup.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom